Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled vs Intramuscular Epinephrine Bioavailability Study
NCT05152901Phase 1Completed
- Sponsor
- De Motu Cordis
- Start
- Jan 2022
- Primary completion
- Jun 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of epinephrine in anaphylaxis (4 arms), sponsored by De Motu Cordis. Primary endpoints: Number of participants with treatment-related adverse events at 66 days, Abnormal and clinically significant abnormal hematology values at 66 days and 3 more. Started Jan 2022; status: completed.
02
Drugs
epinephrine
03
Conditions
anaphylaxis
Beyond the preview
Go deeper on NCT05152901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05152901.